NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis

KalVista Pharmaceuticals, Inc. (KALV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KALV

$27.00

$0.00 (0.00%)

Last trade June 12, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KALV with… →

KALV Key Statistics

As of Jun 12, 2026
Trading
Open
$27.00
Previous Close
$27.00
52-Week Range
9.83–26.85
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.12
Valuation
Market Cap
$1.43B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.40
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.47
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.94
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−118.74%
1-Year Return
+106.26%
Dividend and dates
Avg Volume
3.30M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KALV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+67.18%
2025+90.67%
2024 (partial year)+4.70%

As of June 12, 2026.

KALV Valuation vs Biotechnology Median

Median of 656 stocks
MetricKALVBiotechnology medianvs median
P/S ratio12.4715.2618% below
Profit margin−118.74%0.00%118.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values KalVista Pharmaceuticals, Inc. (KALV) at $1.43B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 275.

KALV last closed at $27.00 on June 12, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $9.83 to $26.85. The latest close sits 174.67% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $114.48M. Profit margin runs at −118.74%. That is 118.7 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −3.94.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 22.4. The price-to-sales ratio is 12.47. On price-to-sales that is 18.31% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at −0.12. Daily returns over the trailing 1 year annualize to a volatility of 73.46%. The trailing one-year price return is +106.26%.

Growth & Income

The record shows no dividend for KALV.

2026 is still running; the price is +67.18% year to date. The record holds one complete calendar year, 2025, which returned +90.67%.

Peer Comparison

KalVista Pharmaceuticals, Inc. (KALV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
KalVista Pharmaceuticals, Inc. KALV $1.43B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. KalVista Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of June 12, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.

Visit website →